PACTR201408000858108暂停未知
A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-82 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis
适应症
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 100 Year(s)（—）
- 性别
- All
入选标准
- •1.Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
- •2.Male or female, aged 18 years or over.
- •3.Body weight (in light clothing and no shoes) ¿ 30 kg.
- •4.Sputum positive for tubercule bacilli (at least 1+ on the IUATLD/WHO scale (Appendix 1)) on smear microscopy at the trial laboratory.
- •5.Drug-Sensitive TB treatment arms subjects should be:
- •a.sensitive to rifampicin by rapid sputum based test (may be sensitive or resistant to isoniazid) AND
- •b.either newly diagnosed for TB or have a patient history of being untreated for at least 3 years after cure from a previous episode of TB.
- •If they are entered into the trial due to being sensitive to rifampicin by rapid sputum based test, however on receipt of the rifampicin resistance testing using an indirect susceptibility test in liquid culture this shows they are rifampicin resistant, they will be:
- •a.Excluded as late exclusions;
- •b.Possibly replaced as determined by the sponsor.
- •MDR-TB treatment arm subjects should be resistant to rifampicin by rapid sputum based test (may be sensitive or resistant to isoniazid).
- •6.A chest x-ray which in the opinion of the investigator is compatible with pulmonary TB.
- •7.Be of non-childbearing potential or using effective methods of birth control.
排除标准
- •1.Any non TB related condition that could compromise the well-being of the subject.
- •2.Being or about to be treated for Malaria.
- •3.Is critically ill & has a diagnosis likely to result in death.
- •4.TB meningitis or other forms of extrapulmonary TB
- •5.History of allergy or hypersensitivity to any of the trial IMP
- •6.For HIV infected subjects any of the following:
- •a.CD4+ count <100 cells/µL;
- •b.Karnofsky score <60%;
- •c.Received IV antifungal medication < 90 days ago;
- •d.WHO Clinical Stage 4 HIV.
- •7.Resistant to fluoroquinolones.
- •8.Resistant to pyrazinamide.
- •9.Participated in other trials with IP within 8 weeks prior to trial start.
- •10.Subjects with any of the following at screening:
- •a.Cardiac arrhythmia requiring medication;
- •b.Prolongation of QT/QTc interval with QTcF >450 ms;
- •c.History of additional risk factors for Torsade de Pointes:
- •d.Any clinically significant ECG abnormality.
- •11.Unstable Diabetes Mellitus which required hospitalization for hyper- or hypo-glycaemia within the past year prior to screening.
- •12.Previous treatment with PA-824.
- •13.For DS-TB: Previous treatment for tuberculosis within 3 years prior to screening. For the MDR-TB: Previous treatment for MDR-TB.
- •14.Any diseases in which the use of the std TB drugs is contra-indicated.
- •15.Use of any drug within 30 days prior to randomisation known to prolong QTc interval.
- •16.Use of systemic glucocorticoids <1 year of screening.
- •17.Subjects recently started or needing to start ART within 1 month after randomization.
- •18.Subjects with the following toxicities at screening as defined by DMID adult toxicity table:
- •a.creatinine >/= grade 2
- •b.CrCl level < 30 mLs/min
- •c.haemoglobin grade 4;
- •d.platelets >/= grade 3
- •e.serum potassium < the lower limit of normal
- •f.AST >/= grade 3
- •g.ALT >/= grade 3
- •h.ALP grade 4
- •i.total bilirubin:
- •o> 2.0 x ULN, when other liver functions are in the normal range
- •o>1.50 x ULN when accompanied by any increase in other liver function tests
研究者
相似试验
进行中（未招募）
不适用
Trial of Aeroquin versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.1Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-IEMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.0 Level: PT Classification code 10011763 Term: Cystic fibrosis lung System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.0 Level: LLT Classification code 10021860 Term: Infection pseudomonas aeruginosa System Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-GBMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy ofMP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution(TIS) in Stable Cystic Fibrosis PatientsEUCTR2010-019634-26-FRMpex Pharmaceuticals, Inc.330
进行中（未招募）
不适用
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsPseudomonas aeruginosa infection in patients suffering from stable Cystic FibrosisMedDRA version: 14.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.0Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-019634-26-DEMpex Pharmaceuticals, Inc.330
进行中（未招募）
1 期
An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam Lysine for Inhalation versus Tobramycin Nebuliser Solution in an Intermittent Aerosolized Antibiotic Regimen in Patients with Cystic FibrosisEnsayo de fase III, abierto, aleatorizado para evaluar la eficacia y seguridad de aztreonam lisina para inhalación frente a una solución de tobramicina para nebulizador en un régimen intermitente de antibiótico en aerosol en pacientes con fibrosis quísticaAdult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection. Pacientes adultos y pediátricos con fibrosis quística (FQ) con infección pulmonar por Pseudomonas aeruginosa (PA).MedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisEUCTR2007-004277-26-ESGilead Sciences Inc274